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We present a unique case of disseminated Leishmaniasis in 
an HIV patient. Two different Leishmania species were iden-
tified by genomic sequencing in both bone marrow and skin. 
The Leishmania infection could be suppressed but not cured, 
despite a high dose of amphotericin B of nearly 65 g over more 
than 6 years.
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Leishmania–HIV coinfection is considered a major threat to the 
lives of HIV-infected patients [1]. It can present as a cutaneous, 
muco-cutaneous, or visceral Leishmaniasis depending on the 
species. Those who are severely immunocompromised with CD4 
T-cell counts <200 cells/μL may present with atypical features. 
Managing such patients is a challenge [2]. We present a case of 
combined muco-cutaneous and visceral Leishmaniasis with 2 dif-
ferent Leishmania species requiring repeated high doses of ampho-
tericin B for more than 6 years to be controlled but without cure.
CASE REPORT
Our case was a 40-year-old Omani male, an intravenous drug 
user with a history of extended travel in the Mediterranean 
region in 1989; he traveled to Oman and southern Yemen, 
where he stayed for 30 days, then crossed the Red Sea to the Suez 
Canal. From there, he had different stops in European countries 
including the United Kingdom, France, Italy, Portugal, Spain, 
and Gibraltar; he stayed for at least 20 to 30 days in each coun-
try. In 1990, he visited Pakistan for 4 weeks.
He presented with oral candidiasis and cystic brain lesions 
in August 2010. He was found to be HIV-positive with cerebral 
toxoplasmosis. His initial HIV viral load was 300 000 copies/mL 
with a CD4 T-cell count of 6 cells/μL. He was started on efavirenz 
600 mg, zidovudine 600 mg, and lamivudine 300 mg once daily 
and received pneumocystis carinii pneumonia  (PCP) prophy-
laxis. He was coinfected with hepatitis C virus, genotype 1B, for 
which interferon and ribavirin treatment was started. He failed 
therapy due to noncompliance, but later, in 2016, he responded 
well to ledipasvir/sofosbuvir treatment.
In 2012, he presented with 5 nodular skin lesions, each <1 cm, 
brownish to purple in color, involving the forehead, fingers, and 
left lower limb. A skin biopsy from the forehead showed macro-
phages in the dermis loaded by Leishman Donovan bodies, and 
cutaneous Leishmaniasis (CL) was diagnosed. The biopsy was 
negative for HHV-8, dysplasia, and malignancy.
He was managed initially with topical paromomycin, but 
a few months later, his condition progressed to disseminated 
muco-cutaneous (MCL) and visceral Leishmaniasis (VL) with 
new nodular lesions on the limbs, ears, and nose, with nasal 
bridge destruction, or “saddle nose.”
He had hepatosplenomegaly and an inguinal lymph node of 
1.2 × 1.0 cm confirmed on computed tomography. The patient 
had pancytopenia, with a hemoglobin level of 7.3 g/dL, throm-
bocytopenia of 30 × 10^9 /L, leukopenia of 1.3 × 10^9 WBC/L, 
and neutropenia of 0.3 × 10^9/L.
 A bone marrow aspirate and biopsy showed Leishmania par-
asites that were also seen in the inguinal lymph node and gastric 
biopsies.
Compliance was an issue. His antiretroviral therapy (ART) 
regimen was changed to emtricitabine 200 mg, tenofovir diso-
proxil fumarate (DF) 300 mg, and efavirenz 600 mg once daily. 
In 2015, his HIV viral load was suppressed, and his absolute 
CD4 count stabilized to between 30 and 80 cells/μL (Table 1).
The patient was managed initially with liposomal amphoter-
icin B, 5 mg/kg for 14 days, and was placed on a maintenance 
dose of 5 mg/kg every 3 weeks for 3 to 5 days. During the first 
year, he showed a good response but then experienced frequent 
relapses. Compliance to the ART and to the Leishmaniasis 
treatment was an issue. Several regimens were used to control 
the relapses, including a combination of liposomal amphoter-
icin and fluconazole to enable shortening treatment duration 
and prolonging the intervals; however, all were unsuccessful. 
With subsequent improvement in ART compliance, his viral 
load was persistently undetectable. However, the CD4 T-cell 
count remained below 80 cells/uL. In 2017, he was started on 
paromomycin orally 500  mg twice a day but did not tolerate 
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it. Currently, he is on a high maintenance dose of liposomal 
amphotericin B 5–7.5  mg/kg for 5  days every 3 weeks. He is 
responding well except if he misses doses.
The latest bone marrow biopsy performed in 2016 showed 
sparse Leishmania parasites; 2 skin biopsies in 2016 and 2017 
showed abundant Leishmania parasites (Figure 1).
Genomic Testing of Leishmania Species
One bone marrow and 2 skin biopsy specimens tested positive in 
the Leishmania genus-specific real-time polymerase chain reaction 
assay [3]. The Leishmania species was determined by amplification of 
the HSP70 (N-terminal fragment) and mini-exon loci and sequencing 
[4]. Sequence analysis demonstrated the presence of a mixture of DNA 
of L. major and L. tropica in the bone marrow specimen, which could 
be explained by either an infection by a hybrid species or by a simul-
taneous infection by 2 distinct Leishmania species. Subsequent analy-
sis of 2 skin biopsy specimens demonstrated the presence of L. tropica 
only, which excludes the possibility that the patient was infected by a 
single hybrid species, as the skin biopsy specimens should have con-
tained this hybrid species as well. Therefore, the patient was simultane-
ously infected by 2 Leishmania species: L. major and L. tropica.
DISCUSSION
Leishmaniasis is a protozoal infection transmitted by the bite 
of female Phlebotomine sand fly. Amastigotes replicate in the 
macrophages of the host, causing muco-cutaneous or visceral 
Leishmaniasis depending on the Leishmania species [5].
Genomic sequencing of species isolated from the bone mar-
row and the skin of our patient showed 2 different species, 
L. tropica and L. major, and the patient probably had Leishmania 
infection before becoming infected with HIV. Although an 
infection with both these Leishmania species normally results 
in cutaneous Leishmaniasis, in severely immunocompromised 
patients, both Leishmania species can disseminate, which 
we believe happened in this patient. Dissemination of “cuta-
neous Leishmania species” has been previously described in 
immune-compromised patients, but to the best of our knowl-
edge, this is the first case in which 2 cutaneous Leishmania spe-
cies could be detected in bone marrow [3, 4].
Oman is a nonendemic area for Leishmaniasis with only 
sporadically reported cases in mainly the 1980s and 1990s. The 
main species involved were L. tropica and L. infantum [6].
L. tropica and L. major are reported to cause CL in Yemen, 
Pakistan, Egypt, and Morocco. In the 1990s, France, Italy, 
Portugal, and Spain reported the most cases of Leishmania–
HIV coinfection in the Mediterranean region, predominantly 
L.  infantum, but with introduction of ART in 1997, these 
reported cases decreased drastically [7].
Leishmaniasis reactivation can occur many years after initial 
infection in immune-compromised patients, which was seen in 
Table 1. Doses of Liposomal Amphotericin B and Patient’s Virological and Immunological Response
Year 2010 2011 2012 2013 2014 2015 2016 2017 2018
Highest CD4 T-cell count, cells/μL 6 169 108 305 288 76 67 49
HIV viral load, copies/mL 316 018 30–109 0–1 367 727 88–3479 <20–545 285 0–568 <20 <20  
Total dose of liposomal amphotericin B, g 0 0 0 3.5 13.3 1.95 14.7 19.8 10.5 
The table demonstrates the highest CD4 T-cell count for our patient per year, along with the range of the HIV viral load during that year. It also shows the total dose of liposomal amphotericin 
B the patient received each year.
Figure 1. A and B, Cutaneous lesions with nodules and destruction of the nasal bridge. C, Skin biopsy with multiple Leishmania parasites (hematoxylin and eosin stain, 
magnification ×600). D, Bone marrow aspirate with sparse Leishmania parasites (Giemsa stain, magnification ×600).
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our patient, who was probably infected 22 years before develop-
ing clinical Leishmaniasis [5, 7].
In severely immunocompromised HIV-infected individuals 
with CD4 T-cell counts <200 cells/uL, atypical presentations of 
cutaneous Leishmaniasis and visceralization are common [5, 
7, 8]. Our patient had lymphadenopathy, hepatosplenomegaly, 
and gut and bone marrow involvement.
Serological tests for Leishmaniasis have low sensitivity in 
HIV patients and are therefore less reliable [5, 7, 8]. Finding 
amastigotes in bone marrow or spleen tissue is considered a 
highly sensitive method for the diagnosis of VL [8], and we did 
not perform serology.
Management of VL-HIV coinfection is challenging. In 
HIV patients, higher relapse rates and treatment failure 
occur more frequently, especially in severely immunocom-
promised individuals with CD4 T-cell counts <200 cells/uL 
[5, 7, 8].
The World Health Organization (WHO) has recommended 
liposomal amphotericin B with a total cumulative dose of 
20–40 mg/kg (equal to 2 g in our patient) as the preferred agent 
to treat VL in HIV-coinfected patients [7–9]. Despite having 
good cure rates ranging from 42% to 85%, frequent relapses 
are seen in HIV-infected patients [9]. This patient responded to 
high-dose liposomal amphotericin B 5–7.5 mg/kg but needed 
frequent, repeated administration daily for 5 days every 3 weeks 
to maintain the status quo.
The patient received far more amphotericin B than recom-
mended in the WHO guideline [9], with an estimated 15–20 g 
per year, and altogether he has received close to 65 g over the 
past 6 years. The latest Infectious Diseases Society of America 
(IDSA) guidelines recommend follow-up treatment in immu-
nocompromised patients with relapse but do not state for how 
long or with which doses [10].
Combination therapies with pentamidine, paromomycin, 
fluconazole, or allopurinol are recommended in cases with 
multiple relapses. This approach can lead to better response and 
reduced relapse rates [7–9] but has higher toxicity profiles [9]; 
our patient tolerated amphotericin B well.
Several studies have demonstrated that miltefosine is a 
well-tolerated drug even in long-term use for treatment of 
VL-HIV coinfection, with better safety profiles [7–9, 11], 
but we do not have access to miltefosine. A combination of 
amphotericin B and miltefosine is a possibility in cases like 
this patient.
Response to treatment depends on the virulence of the caus-
ative Leishmania species [8, 11], and most of previous studies 
were carried out in Europe and Ethiopia involving L. infantum 
and L. donovani, respectively [8, 13]. More studies are needed to 
assess the efficacy of those drugs in patients infected with other 
Leishmania species. The IDSA guidelines recommend genotyp-
ing of the Leishmania species, and treatment efficacy may vary 
depending on the Leishmania genotype; however, treatment 
recommendations do not consider different genotypes [10].
Despite starting ART and having good viral suppression, 
the patient failed to have good immunological recovery. 
Visceral Leishmaniasis hinders immunological recovery and 
increases HIV viral replication. This is attributed to shar-
ing the same immunological mechanism involving dendritic 
cells, specific T-helper type I cells, and macrophages [5, 7, 8, 
11]. Starting ART can reduce the incidence of VL-HIV coin-
fection and the rate of relapses, but relapses can still occur 
with an improved CD4 count and an undetectable HIV viral 
load [7, 11, 12, 14].
Our patient failed to maintain immunological recovery and 
is probably going to require lifelong treatment with amphoter-
icin B if more efficient treatment of his Leishmania infection is 
not available.
Acknowledgments
We thank Florence Robert-Gangneux for help and assistance with the 
isolation of the nucleic acids from the biopsy specimens. We also thank 
Christophe Ravel from the French Reference Center of Leishmaniasis 
(University of Montpellier) for his help with the hypothesis of the hybrid.
Potential conflicts of interest. All authors: no reported conflicts of 
interest. All authors have submitted the ICMJE Form for Disclosure of 
Potential Conflicts of Interest. Conflicts that the editors consider relevant to 
the content of the manuscript have been disclosed.
References
1. Pagliano P, Esposito S. Visceral leishmaniosis in immunocompromised host: an 
update and literature review. J Chemother 2017; 29:261–6.
2. Ponte-Sucre  A, Gamarro  F, Dujardin  JC, et  al. Drug resistance and treatment 
failure in leishmaniasis: a 21st century challenge. PLoS Negl Trop Dis 2017; 
11:e0006052.
3.  Wortmann G, Sweeney C, Houng HS, et al. Rapid diagnosis of leishmaniasis by 
fluorogenic polymerase chain reaction. Am J Trop Med Hyg 2001; 65:583–7.
4. Van der Auwera G, Ravel C, Verweij JJ, et al. Evaluation of four single-locus mark-
ers for Leishmania species discrimination by sequencing. J Clin Microbiol 2014; 
52:1098–104.
5. Lindoso JA, Cunha MA, Queiroz IT, Moreira CH. Leishmaniasis-HIV coinfec-
tion: current challenges. HIV AIDS (Auckl) 2016; 8:147–56.
6. Alvar J, Vélez ID, Bern C, et al; WHO Leishmaniasis Control Team. Leishmaniasis 
worldwide and global estimates of its incidence. PLoS One 2012; 7:e35671.
7. Monge-Malio B, Norman FF, Cruz I, et al. Visceral Leishmaniasis and HIV coin-
fection in the Mediterranean region. PLoS Negl Trop Dis 2014; 8:1–6.
8. van Griensven J, Carrillo E, López-Vélez R, et al. Leishmaniasis in immunosup-
pressed individuals. Clin Microbiol Infect 2014; 20:286–99.
9. Monge-Malio B, Lopez -Vélez R. Treatment options for visceral leishmaniasis and 
HIV coinfection. AIDS Rev 2016; 18:32–43.
10. Aronson N, Herwaldt BL, Libman M, et al. Diagnosis and treatment of leishman-
iasis: clinical practice guidelines by the Infectious Diseases Society of America 
(IDSA) and the American Society of Tropical Medicine and Hygiene (ASTMH). 
Clin Infect Dis 2016; 63:1539–57.
11. Alvar  J, Aparicio  P, Aseffa  A, et  al. The relationship between leishmaniasis 
and AIDS: the second 10  years. Clin Microbiol Rev 2008; 21:334–59, table of 
contents.
12. Cota GF, de Sousa MR, Rabello A. Predictors of visceral leishmaniasis relapse in 
HIV-infected patients: a systematic review. PLoS Negl Trop Dis 2011; 5:e1153.
13. Diro E, Ritmeijer K, Boelaert M, et al. Long-term clinical outcomes in visceral 
leishmaniasis/human immunodeficiency virus–coinfected patients during and 
after pentamidine secondary prophylaxis in ethiopia: a single-arm clinical trial. 
Clin Infect Dis 2017; 66:444–51.
14. Alemayehu M, Wubshet M, Mesfin N. Magnitude of visceral leishmaniasis and 
poor treatment outcome among HIV patients: meta-analysis and systematic 
review. HIV AIDS (Auckl) 2016; 8:75–81.
D
ow
nloaded from
 https://academ
ic.oup.com
/ofid/article-abstract/5/12/ofy323/5232658 by Erasm
us U
niversiteit R
otterdam
 user on 01 August 2019
